Studies at a Glance
Moderate-to-Severe Asthma
Studies at a Glance
Moderate-to-Severe Asthma
Embedded Files
Moderate-to-Severe Asthma
IRB No. HUM00244175
IRB No. HUM00244175
AstraZeneca | D8210C00003 | Lugogo
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
IRB No. HUM00206820
Sanofi | LPS16676 | Lugogo
Study assessing the long-term effect of Dupilumab (Dupixent) on prevention of lung function decline in patients with uncontrolled moderate to severe asthma.
IRB No. HUM00196809
AstraZeneca | D3250C00059 | Lugogo
Study designed to evaluate the effect of Benralizumab (Fasenra) on patients with uncontrolled severe, eosinophilic asthma despite a high dose ICS-based treatment regimen with an eosinophilic phenotype.
Other Studies
Moderate Asthma | Lung Cancer Screening | Future Participant Registry
Other Studies
Moderate Asthma | Lung Cancer Screening | Future Participant Registry
ANCHOR
ANCHOR
IRB No. HUM00262890
AstraZeneca | Lugogo
Adults 18 and older who have been diagnosed with asthma may be eligible to participate in a research study to evaluate the efficacy of AIRSUPRA in reducing asthma attacks. AIRSUPRA is a new FDA-approved therapy which combines the rapid relief of albuterol with the long-term anti-inflammatory benefits of budesonide. Eligible participants will receive access to this cutting-edge asthma treatment at no cost. To see if you qualify, please visit umhealthresearch.org/anchor.
Adults 18 and older who have been diagnosed with asthma may be eligible to participate in a research study to evaluate the efficacy of AIRSUPRA in reducing asthma attacks. AIRSUPRA is a new FDA-approved therapy which combines the rapid relief of albuterol with the long-term anti-inflammatory benefits of budesonide. Eligible participants will receive access to this cutting-edge asthma treatment at no cost. To see if you qualify, please visit umhealthresearch.org/anchor.
LIGHTHOUSE
LIGHTHOUSE
IRB No. HUM00234751
Roche | Lugogo
The purpose of this study is to collect blood samples and medical information to help develop and evaluate a blood test that can screen for many cancers from a single blood draw. This test aims to find many different types of cancers, including but not limited to: lung, colorectal, ovarian, pancreatic, liver, bladder, stomach and esophageal cancers.
Investigator Initiated | Lugogo
Proactively evaluate potential subjects with asthma who have expressed interest in participating in clinical asthma research trials at Michigan Medicine.
Joining one of our study trials may be right for one of your patients.
Joining one of our study trials may be right for one of your patients.
Thank you for your consideration and referrals.
Thank you for your consideration and referrals.
Report abuse